区域枸橼酸抗凝与全身肝素抗凝对连续性肾脏替代治疗滤器寿命及危重急性肾损伤患者死亡率的影响:一项随机临床试验
该平行组随机多中心临床试验在德国26个中心开展,纳入596例严重急性肾损伤或具备肾脏替代治疗临床指征的危重患者,比较区域枸橼酸抗凝(目标离子钙1.0~1.40 mg/dL)与全身肝素抗凝(目标活化部分凝血活酶时间45~60秒)。区域枸橼酸组中位滤器寿命47小时,显著长于肝素组的26小时(差值15小时,95%CI 11~20小时,P<.001)。90天全因死亡率两组无显著差异(51.2% vs 53.6%;未校正HR 0.91,95%CI 0.72~1.13,P=.38)。区域枸橼酸组出血并发症显著更少,但新发感染显著更多。试验提前终止,对死亡率终点把握度不足。
要点
- 危重急性肾损伤行连续性肾脏替代治疗时,区域枸橼酸抗凝(目标离子钙1.0~1.40 mg/dL)较全身肝素抗凝(目标活化部分凝血活酶时间45~60秒)中位滤器寿命延长15小时(47 vs 26小时,95%CI 11~20小时,P<.001)。
- 90天全因死亡率区域枸橼酸组51.2% vs 肝素组53.6%,未校正HR 0.91(95%CI 0.72~1.13,P=.38),无显著差异;试验提前终止,对死亡率终点把握度不足。
- 区域枸橼酸组出血并发症15/300(5.1%)显著少于肝素组49/296(16.9%)(差值-11.8%,95%CI -16.8%~-6.8%,P<.001)。
- 区域枸橼酸组新发感染204/300(68.0%)显著多于肝素组164/296(55.4%)(差值12.6%,95%CI 4.9%~20.3%,P=.002)。
- 38个预设次要终点中34个无显著差异。
适用人群与场景
- 德国26个中心收治的危重患者,存在严重急性肾损伤或具备启动肾脏替代治疗的临床指征,需行连续性肾脏替代治疗。
诊断标准与关键阈值
- 区域枸橼酸抗凝组:目标离子钙水平1.0~1.40 mg/dL。
- 全身肝素抗凝组:目标活化部分凝血活酶时间45~60秒。
处置流程与药物剂量
- 区域枸橼酸抗凝:在体外透析回路滤器前向血液中加入枸橼酸溶液,目标离子钙1.0~1.40 mg/dL。
- 全身肝素抗凝:目标活化部分凝血活酶时间45~60秒。
研究设计与关键结果
- 平行组、随机、多中心临床试验,德国26个中心,2016年3月至2018年12月开展(末次随访2020年1月21日),纳入596例危重急性肾损伤或具备肾脏替代治疗临床指征的患者,随机分为区域枸橼酸抗凝组(n=300)与全身肝素抗凝组(n=296);638例随机化患者中596例(93.4%)完成试验,平均年龄67.5岁,女性183例(30.7%)。
- 共同主要终点为滤器寿命与90天死亡率:区域枸橼酸组中位滤器寿命47小时(IQR 19~70小时)vs 肝素组26小时(IQR 12~51小时),差值15小时(95%CI 11~20小时),P<.001。
- 90天全因死亡率:区域枸橼酸组150/300 vs 肝素组156/296,Kaplan-Meier估计百分比51.2% vs 53.6%,未校正差值-2.4%(95%CI -10.5%~5.8%),未校正HR 0.91(95%CI 0.72~1.13),未校正P=.38;校正差值-6.1%(95%CI -12.6%~0.4%),主要校正HR 0.79(95%CI 0.63~1.004),主要校正P=.054。
- 38个预设次要终点中34个无显著差异;区域枸橼酸组出血并发症15/300(5.1%)vs 肝素组49/296(16.9%),差值-11.8%(95%CI -16.8%~-6.8%),P<.001;区域枸橼酸组新发感染204/300(68.0%)vs 肝素组164/296(55.4%),差值12.6%(95%CI 4.9%~20.3%),P=.002。
证据类型、等级与局限
- 证据类型:平行组、随机、多中心临床试验(RCT)。
- 作者结论:在危重急性肾损伤接受连续性肾脏替代治疗的患者中,区域枸橼酸抗凝较全身肝素抗凝显著延长滤器寿命;试验提前终止,对死亡率终点的把握度不足,无法就抗凝策略对死亡率的影响得出结论。
- 局限:试验提前终止,对死亡率终点把握度不足。
对床旁实践的改变
- 对于危重急性肾损伤需行连续性肾脏替代治疗的患者,区域枸橼酸抗凝(目标离子钙1.0~1.40 mg/dL)较全身肝素抗凝(目标活化部分凝血活酶时间45~60秒)可延长滤器寿命并减少出血并发症,但新发感染更多;作者结论指出该试验提前终止、对死亡率终点把握度不足,未能就抗凝策略对死亡率的影响得出结论。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT02669589
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although current guidelines suggest the use of regional citrate anticoagulation (which involves the addition of a citrate solution to the blood before the filter of the extracorporeal dialysis circuit) as first-line treatment for continuous kidney replacement therapy in critically ill patients, the evidence for this recommendation is based on few clinical trials and meta-analyses.
OBJECTIVE: To determine the effect of regional citrate anticoagulation, compared with systemic heparin anticoagulation, on filter life span and mortality.
DESIGN, SETTING, AND PARTICIPANTS: A parallel-group, randomized multicenter clinical trial in 26 centers across Germany was conducted between March 2016 and December 2018 (final date of follow-up, January 21, 2020). The trial was terminated early after 596 critically ill patients with severe acute kidney injury or clinical indications for initiation of kidney replacement therapy had been enrolled.
INTERVENTIONS: Patients were randomized to receive either regional citrate anticoagulation (n = 300), which consisted of a target ionized calcium level of 1.0 to 1.40 mg/dL, or systemic heparin anticoagulation (n = 296), which consisted of a target activated partial thromboplastin time of 45 to 60 seconds, for continuous kidney replacement therapy.
MAIN OUTCOMES AND MEASURES: Coprimary outcomes were filter life span and 90-day mortality. Secondary end points included bleeding complications and new infections.
RESULTS: Among 638 patients randomized, 596 (93.4%) (mean age, 67.5 years; 183 [30.7%] women) completed the trial. In the regional citrate group vs systemic heparin group, median filter life span was 47 hours (interquartile range [IQR], 19-70 hours) vs 26 hours (IQR, 12-51 hours) (difference, 15 hours [95% CI, 11 to 20 hours]; P < .001). Ninety-day all-cause mortality occurred in 150 of 300 patients vs 156 of 296 patients (Kaplan-Meier estimator percentages, 51.2% vs 53.6%; unadjusted difference, -2.4% [95% CI, -10.5% to 5.8%]; unadjusted hazard ratio, 0.91 [95% CI, 0.72 to 1.13]; unadjusted P = .38; adjusted difference, -6.1% [95% CI, -12.6% to 0.4%]; primary adjusted hazard ratio, 0.79 [95% CI, 0.63 to 1.004]; primary adjusted P = .054). Of 38 prespecified secondary end points, 34 showed no significant difference. Compared with the systemic heparin group, the regional citrate group had significantly fewer bleeding complications (15/300 [5.1%] vs 49/296 [16.9%]; difference, -11.8% [95% CI, -16.8% to -6.8%]; P < .001) and significantly more new infections (204/300 [68.0%] vs 164/296 [55.4%]; difference, 12.6% [95% CI, 4.9% to 20.3%]; P = .002).
CONCLUSIONS AND RELEVANCE: Among critically ill patients with acute kidney injury receiving continuous kidney replacement therapy, anticoagulation with regional citrate, compared with systemic heparin anticoagulation, resulted in significantly longer filter life span. The trial was terminated early and was therefore underpowered to reach conclusions about the effect of anticoagulation strategy on mortality.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02669589.
参考来源
- Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2020. PMID: 33095849. doi:10.1001/jama.2020.18618
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。